Pharmacotherapy of mild cognitive impairment by Gauthier, Serge
here is great interest in mild cognitive impair-
ment (MCI) as an intermediate state between normal
aging and dementia.In its broadest sense,the term MCI
encompasses a number of causes of cognitive decline,
each with their own symptomatic treatment (Table I).
This list is not exhaustive,but includes the most common
causes of consultation in memory clinics for cognitive
decline over age 50: MCI of dysthymic, vascular, and
amnestic etiologies.
1 This article will focus on the phar-
macotherapy of the amnestic type of MCI because of the
associated high risk of conversion to Alzheimer’s disease
(AD) and the availability of randomized clinical trials
(RCTs) studying the safety and efficacy of a number of
medications, over periods ranging from 6 months to 
4 years.
What is amnestic MCI?
Amnestic MCI was defined by Petersen et al
2 in the con-
text of a natural observation study,which demonstrated
a rate of conversion to AD that was well above the inci-
dence of age-matched populations.The original amnes-
tic MCI criteria are as follows
2:
• Memory complaint, preferably corroborated by an
informant.
• Memory impairment relative to age- and education-
matched normal subjects.
• Relatively normal general cognitive function.
• Largely intact activities of daily living (ADL).
• Not demented.
A more recent subclassification of MCI has been pro-
posed by Petersen
3 on the basis of findings from cogni-
tive testing in larger number of subjects:
• Amnestic or single-memory MCI.
• Multiple-domain MCI.
• Single non–memory-domain MCI.
The first two groups (single-memory MCI and multiple-
domain [including memory] MCI) seem to share the
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Amnestic mild cognitive impairment (MCI) can be consid-
ered as a state with a high risk of developing Alzheimer’s
disease within 5 years, or as a prodromal stage of this con-
dition. Randomized clinical trials comparing the acetyl-
cholinesterase inhibitor donepezil with placebo have
shown some symptomatic benefit on (i) cognition in one
short-term (6-month) study; and (ii) conversion to demen-
tia in one long-term (3-year) study, but not for the full
duration of the study, except in subjects with the
apolipoprotein E4 (APOE-4) mutation, in whom the ben-
efit was sustained throughout the 3 years. Results from
studies on galantamine are still being analyzed; and a
rivastigmine study will close in the fall of 2004. It is pre-
mature to recommend that acetylcholinesterase inhibitors
be used systematically in amnestic MCI. However, impor-
tant lessons have been learned from studies in this pro-
dromal stage of AD, allowing the testing of hypotheses
for disease modification.  
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(e-mail: serge.gauthier@mcgill.ca)same risk of conversion to AD,whereas the third group
(single non–memory-domain MCI) may be a prodrome
to the nonAD dementias.
For the purpose of RCTs,operational criteria with specific
inclusion/exclusion criteria have been specified.The crite-
ria for the study completed by the Alzheimer Disease
Cooperative Study comparing donepezil with tocopherol
and placebo
4 are listed in Table II; this study will be
referred to in this monograph as the Memory Impairment
Study (MIS).Although not fully analyzed and published,
entry criteria for the twin studies (with and without mag-
netic resonance imaging [MRI]) comparing galantamine
and placebo are available
5 and are summarized in Table
III.The Investigation into the Delay to Diagnosis of AD
with Exelon (rivastigmine) (InDDEx) study is not yet
completed,but the entry criteria of this 4-year RCT com-
paring rivastigmine with placebo have been published.
6
These are listed in Table IV for purposes of comparison
between the MIS, the galantamine studies, and the
InDDEx study.
Hypothesis leading to RCTs for amnestic MCI
The fact that most patients with amnestic MCI convert
to AD led to the hypothesis that they were suffering from
a reduction in cholinergic activity,which is the basis for
the so-called “cholinergic hypothesis of AD,”at least in
terms of its mainline symptomatic therapy.On the other
hand,observations made by DeKosky et al
7 of increased
choline acetyltransferase activity in the superior frontal
cortex and hippocampus of subjects with MCI compared
with controls and with subjects with mild AD suggested
that a cholinergic deficit in amnestic MCI may not be as
prominent as was initially postulated.The safety and effi-
cacy of the acetylcholinesterase inhibitors (AChEIs)
donepezil,galantamine,and rivastigmine have been stud-
ied extensively versus placebo in amnestic MCI .To date,
results are available from a short-term (6-month) symp-
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Selected abbreviations and acronyms
AChEI acetylcholinesterase inhibitor
AD Alzheimer’s disease
ADAS-cog Alzheimer Disease Assessment Scale–Cognitive
Component
ADL activities of daily living
CDR clinical dementia rating
CGIC Clinical Global Impression of Change
InDDEx Investigation in the Delay to Diagnosis of AD
with Exelon (rivastigmine)
MCI mild cognitive impairment
MIS Memory Impairment Study
PGA patient global assessment
RCT randomized clinical trial
Table I. Causes of mild cognitive impairment. 
Modified from reference 1: Gauthier S, Touchon J. Subclassification of mild
cognitive impairment in research and in clinical practice. In: Gauthier S,
Scheltens P, Cummings JL, eds. Alzheimer’s Disease and Related Disorders.
London, UK: Martin Dunitz; 2004:61-79. Copyright © 2004. Martin Dunitz.
Etiology Symptomatic treatment
Amnestic Cholinesterase inhibitors? 
Cognitive training?
Cerebrovascular Control of vascular risk factors
Dysthymic Antidepressants; psychotherapy
Hypothyroidism Thyroid supplementation
Substance abuse Abstinence; psychotherapy
Table II. Entry criteria into the Alzheimer Disease Cooperative Study (here referred to as the Memory Impairment Study [MIS]). ADL, activities of daily
living; CDR, Clinical Dementia Rating; MMSE, Mini-Mental-State Examination; CT, computed tomography; MRI, magnetic resonance imaging.
Modified from reference 4: Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer’s disease and normal aging
for clinical trials. Arch Neurol. 2004;61:59-66. Copyright © 2004. American Medical Association.
• Memory complaint, corroborated by an informant
• Abnormal memory function, documented by delayed recall of one paragraph from the Logical Memory III subtest of the
Wechsler Memory Scale–Revised, adjusted for age and education
• Normal general cognitive function as determined by a clinician’s judgment based on the CDR and MMSE
• No or minimal impairment in ADL
• Not clinically demented 
• Age 55 to 90 years
• In good general health with no significant cerebral vascular disease, with Hachinski Ischemic Score ≤4 
• Not depressed, with a Hamilton Depression Rating Scale score ≤12
• CT or MRI without infection, infarction, or focal lesions
• CDR global score 0.5, with ≥0.5 in the memory domaintomatic study with donepezil and long-term studies with
galantamine and donepezil.
Etiological approaches to AD include anti-inflammatory
drugs and it was logical to test cyclooxygenase-2 (COX-2)–
selective inhibitors, such as refecoxib. Unfortunately,
there have only been negative results reported from such
studies and so these agents will not be discussed further
in this monograph.Non–transmitter-specific drugs,such
as piracetam,have also been tested,with negative results
and will not be discussed further.
Trial designs and outcomes to test 
symptomatic benefit in amnestic MCI
There has been much interest in the short-term benefit
of drugs in amnestic MCI, with particular attention to
cognitive outcomes. A 6-month study comparing
donepezil with placebo was performed using parallel
groups, with the Alzheimer’s Disease Assessment
Scale–Cognitive Component (ADAS-cog)
8 and a
Clinical Global Impression of Change modified for MCI
(CGIC-MCI) as primary outcomes;secondary outcomes
included the New York University (NYU) Paragraph
test,Digit Span Backwards test,Symbol Digit Modalities
test,and a Patient Global Assessment (PGA).
9
Trial design and outcomes to test delay in
conversion from amnestic MCI to AD
The possibility of delaying conversion from amnestic
MCI to AD has attracted a lot of interest since it offers
good face validity.Designs have included parallel groups
with conversion to AD as a primary end point.This con-
version has been defined operationally in different ways,
ranging from a clinical opinion to a change in the Clinical
Dementia Rating (CDR) scale Global Score from 0.5 to
1. Conversion committees were asked to monitor con-
versions taking place in the different RCTs and to ana-
lyze the key factors leading to conversion.This informa-
tion will be very useful to design future RCTs and also
for practicing clinicians who want reassurance in the very
early diagnosis of AD,when ADL changes are minimal.
Secondary outcomes in these studies include a number
of cognitive,ADL,and global outcomes.
Results of symptomatic studies
The 6-month donepezil RCT has shown a statistically sig-
nificant but small improvement in ADAS-cog,driven by
the ADAS-cog Immediate Word Recall test.In the fully
evaluable population, scores on the NYU Paragraph
Immediate and Delayed Recall tests as well as the Digit
Span Backwards test were significantly better in the
donepezil group.
9The CGIC measured by the clinician
failed to detect a difference,but the self-rated impression
of change from the subjects (PGA) showed a highly sta-
tistically significant difference between donepezil and
placebo.Side effects were predominantly gastrointesti-
nal (diarrhea, nausea, and vomiting) and nocturnal
(abnormal dreams) at a higher frequency than patients
with AD at a similar dose of 10 mg at bedtime.
10
Results of conversion studies
The 2-year galantamine studies showed no difference in
the primary analysis of conversion from amnestic MCI to
AD.
11Analysis of secondary outcomes is under way,but it
is apparent that a reduced rate of whole-brain atrophy has
been found in patients treated with galantamine.
12
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Table III. Entry criteria in the galantamine studies. ADL, activities of daily
living; CDR, Clinical Dementia Rating; NYU, New York University.
Modified from reference 5: Gold M, Wang D, Truyen L. Galantamine for
the treatment of mild cognitive impairment: 2 double-blind, placebo-con-
trolled studies. Paper presented at: 11th Congress of the International
Psychogeriatric Association; August 17-22, 2003; Chicago, Ill.
• Cognitive decline of gradual onset and slow progression
• Abnormal memory function, documented by a Delayed
Recall Score ≤10 on the NYU Paragraph Recall test
• Insufficient impairment on ADL to warrant a diagnosis of
dementia
• Age 50 or older
• CDR global score 0.5, with ≥0.5 in the memory domain
Table IV. Entry criteria in the Investigation in the Delay to Diagnosis of AD
with Exelon (InDDEx) study. CDR, Clinical Dementia Rating; NYU,
New York University.
Modified from reference 6: Feldman H, Scheltens P, Scarpini E, et al.
Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:
1199-1201. Copyright © 2004. Lippincott, Williams and Wilkins.
• Memory complaints
• Abnormal memory function, documented by the NYU
Delayed Paragraph Recall with a cutoff inclusion <9
• Not clinically demented
• Ages 55 to 85 years
• Not depressed, with a Hamilton Depression Rating Scale
score <13, with Item 1 (depressed mood) score ≤1
• CDR global score 0.5Baseline demographics of the 3-year MIS have been
reported
4 and are listed in Table V.An annual conversion
rate of the order of 13% was reached with this amnestic
MCI population,which most investigators would consider
as prodromal AD.
13
Results of the primary analysis of MIS have been pre-
sented at the 9th International Conference on Alzheimer’s
Disease and Related Disorders:there was no difference in
the primary analysis of conversion from amnestic MCI to
AD after 3 years.
14 Analysis of secondary outcomes is
under way,and it is already apparent that there is a statis-
tically significant delay of conversion between subjects
treated with donepezil and placebo at 6,12,and 18 months
into the study,with the conversion curves overlapping at
24,30,and 36 months.Patients carrying the apolipoprotein
E4 (APOE-4) mutation were at a much higher risk of con-
verting to AD and had a statistically significant protective
effect from conversion on treatment with donepezil from
month 6 until month 36.
The results of the 4-year rivastigmine study should be
available early 2005.
Tolerability of AChEI in long-term amnestic MCI
appears to be similar to patients with AD in terms of a
predominance of gastrointestinal transient side effects.
Their incidence and severity are slightly higher than in
AD and lead to a higher rate of discontinuation,partic-
ularly in the first year of treatment.
Lessons so far
Although not all the data are in and not all subanalyses
on the available data have been performed,it is apparent
that the AChEI class does not delay the conversion from
amnestic MCI to AD beyond 18 months.This suggests
that the AChEIs have a symptomatic and potentially clin-
ically significant effect,but one that is transient.This is
congruent with the AD2000 study,which demonstrated a
sustained benefit of donepezil on cognition using the
Mini-Mental-State Examination (MMSE) and an ADL
measure over 2 years.
15
In terms of safety, the gastrointestinal side effects of
AChEIs appear to be more prominent in MCI than in AD,
and lower doses may be preferred in both RCTs and clin-
ical practice.
Earlier diagnosis of AD has been facilitated by research on
amnestic MCI.More patients presenting because of mem-
ory complaints will get a full assessment,seeking reversible
causes,concomitant disorders,and risk factors,all of which
are amenable to treatment.AChEIs will be one option for
treatment,most likely at lower doses than are usual in AD.
This option should not be recommended at this stage of
our knowledge,but should not be denied for people who
ask for it.It is premature to recommend that subjects with
amnestic MCI be screened for APOE-4 genotype and only
those with the APOE-4 mutation be treated,but genotyp-
ing must be done at entry into RCTs for MCI because of
its strong effect on conversion rate;in other words,we must
stratify for APOE-4 alleles between treatment arms.
The future
It is still early days in the analysis of what has been
achieved with AChEIs and noncholinergic drugs in amnes-
tic MCI.Already, RCT protocols are being created for
other classes of drugs with (i) potential cognitive effects
demonstrable in short-term 6-month studies; and (ii)
potential effects delaying conversion to AD over 3 years.
Placebo-controlled studies are not an issue in amnestic
MCI,in contrast to mild-to-moderate AD.The prodromal
stage of AD may be the most promising stage to test the
efficacy and safety of disease-modifying drugs,when the
neurons are still salvageable. ❏
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Table V. Baseline characteristics of the Memory Impairment Study (MIS).
Values are means±SD. CDR, Clinical Dementia Rating; MMSE, Mini-
Mental-State Examination; ADCS, Alzheimer Disease Cooperative
Study; MCI, mild cognitive impairment; ADL, activities of daily living.
Reproduced from reference 4: Grundman M, Petersen RC, Ferris SH, et al.
Mild cognitive impairment can be distinguished from Alzheimer’s disease
and normal aging for clinical trials. Arch Neurol. 2004;61:59-66. Copyright
© 2004. American Medical Association.
MMSE score 27.3±1.9
Immediate paragraph recall score 6.3±3.1
Delayed paragraph recall score 3.3±2.5
CDR global score 0.5±0
CDR sum of boxes 1.8±0.8
• Memory score 0.6±0.2
• Orientation score  0.3±0.3
• Judgment score 0.4±0.2
• Community affairs score 0.2±0.3
• Hobbies score 0.3±0.3
• Personal care score 0±0.1
Hamilton Depression Scale score  2.7±2.8
Hachinski score 0.5±0.7
Global Deterioration Scale 2.7±0.6
ADCS MCI-ADL score 45.9±5.1Pharmacotherapy of mild cognitive impairment - Gauthier Dialogues in Clinical Neuroscience - Vol 6 . No.4 . 2004
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Farmacoterapia del deterioro cognitivo leve
El deterioro cognitivo leve con amnesia puede con-
siderarse como un estado con un alto riesgo de
desarrollar la enfermedad de Alzheimer dentro de
cinco años, o como una etapa prodrómica de esta
enfermedad. Ensayos clínicos aleatorios que com-
paran el donepezilo, inhibidor de la acetilcolines-
terasa, con placebo han mostrado beneficios para
algunos síntomas: (a) de tipo cognitivo en un estu-
dio a corto plazo (6 meses) y (b) en la conversión a
demencia en un estudio a largo plazo (3 años), pero
no para la duración completa del estudio, excepto
en sujetos con la mutación del gen de la apolipo-
proteína E4 (APOE-4), en quienes el beneficio se
mantuvo a lo largo de los tres años. Aun se están
analizando los resultados de estudios con galanta-
mina y de uno con rivastigmina que terminará en
el otoño de 2004. Es prematuro recomendar el
empleo sistemático de inhibidores de la acetilcoli-
nesterasa en el deterioro cognitivo leve con amne-
sia. Sin embargo, se han aprendido importantes lec-
ciones de estos estudios en esta etapa prodrómica
de la enfermedad de Alzheimer, las que han per-
mitido el análisis de hipótesis para la modificación
de la enfermedad. 
Pharmacothérapie du déficit cognitif léger
(MCI)
Le déficit cognitif léger (Mild Cognitive Impairment,
MCI) avec amnésie peut être considéré comme un
état à risque élevé de développement d’une mala-
die d’Alzheimer (MA) dans les 5 ans, ou comme une
phase prodromique de cette pathologie. Des essais
cliniques randomisés comparant le donépézil, inhi-
biteur de l’acétylcholinestérase, à un placebo ont
montré un certain bénéfice symptomatique sur : (1)
la cognition dans une étude à court terme (6 mois) ;
et (2) la transformation en démence dans une
étude à long terme (3 ans), mais pas pour toute la
durée de l’étude, sauf pour les sujets présentant la
mutation de l’apolipoprotéine E4 (APOE-4), chez
lesquels le bénéfice était maintenu pendant les 3
ans. Des résultats d’études sur la galantamine sont
en cours d’analyse, et une étude sur la rivastigmine
s’achèvera en automne 2004. Il est prématuré de
recommander l’utilisation systématique des inhibi-
teurs de l’acétylcholinestérase dans le MCI avec
amnésie. Cependant, des leçons importantes ont
été tirées des études sur ce stade prodromique de
la MA, permettant d’évaluer des hypothèses pour
modifier la maladie.
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